Date: 2014-11-12
Type of information: Collaboration agreement
Compound: vax-TyVi, VA-MENGOC-BC, vax-SPIRAL
Company: Abivax (France) the Finlay Institute (Cuba)
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism:
Disease: typhoid, meningococcus, and leptospirosis
Details: * On November 12, 2014, Abivax, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, announced that it has signed an agreement with The Finlay Institute, Havana, Cuba, that will allow it to commercialise vaccines against typhoid, meningococcus, and leptospirosis, in Asian and Latin American markets.
Under the terms of the agreement, Abivax will gain exclusive and non-exclusive distribution rights for three vaccines currently marketed successfully by The Finlay Institute in Cuba. These vaccines are vax-TyVi – targeting Typhoid, VA-MENGOC-BC – targeting Groups B & C Meningococcus and vax-SPIRAL - targeting Leptospirosis. Abivax will have rights to commercialise these products in a range of countries in Asia, including India, Indonesia and the Philippines, and Latin America, including Brazil, Mexico and Uruguay. As a result, Abivax has gained distribution rights to a number of exciting opportunities including typhoid in India, which is a market estimated to be worth over $600 million per annum. The Finlay Institute will be responsible for the cost competitive production of all three vaccines.
Abivax intends to build a commercial network to market these vaccines by appointing carefully selected partners in each of these countries. Abivax will select its partners based on a number of criteria including ability to service the selected market, portfolio fit and strength of relations with the local authorities. Abivax will be responsible for the regulatory filings in each market, supported by its local partner. The first sales from this agreement are expected in 2015. Abivax will generate further value from this commercial network by using it to market products such as ABX203, a therapeutic vaccine candidate for chronic hepatitis B, which it is currently developing. ABX203 was in-licensed by ABIVAX from the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), as announced in February 2014.
Financial terms:
Latest news:
